Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338).

Autor: Petricoul, Olivier, Nazarian, Arman, Schuehly, Uwe, Schramm, Ursula, David, Olivier J., Laurent, Didier, Praestgaard, Jens, Roubenoff, Ronenn, Papanicolaou, Dimitris A., Rooks, Daniel

Publikováno v: Clinical Pharmacokinetics; Jan2023, Vol. 62 Issue 1, p141-155, 15p

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials

Autor: Lambertini, Matteo, Martel, Samuel, Campbell, Christine, Guillaume, Sébastien, Hilbers, Florentine, Schuehly, Uwe, Korde, Larissa, Azim, Hatem, Di Cosimo, Serena, Tenglin, Richard, Huober, Jens, Baselga, José, Moreno-Aspitia, Alvaro, Piccart-Gebhart, Martine, Gelber, Richard, De Azambuja, Evandro, Ignatiadis, Michail

Publikováno v: Cancer
Cancer, Wiley, 2019, 125 (2), pp.307-316. ⟨10.1002/cncr.31784⟩

International audience; BACKGROUND:Limited data exist on the safety of using anti-human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::6fa782c42737326ae8af838d6d136f93
http://hdl.handle.net/11567/938060

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Autor: Lambertini M; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium., Martel S; Department of Hemato-Oncology, CISSS Montérégie-Centre/Hôpital Charles-Le Moyne, Université de Sherbrooke, Quebec, Canada., Campbell C; Frontier Science, Kingussie, United Kingdom., Guillaume S; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium., Hilbers FS; Breast International Group, Brussels, Belgium., Schuehly U; Novartis Pharma AG, Basel, Switzerland., Korde L; National Cancer Institute, Bethesda, Maryland., Azim HA Jr; Department of Medicine, Division of Hematology/Oncology, American University of Beirut, Beirut, Lebanon., Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tenglin RC; Rapid City Regional Hospital, Rapid City, South Dakota., Huober J; Breast Center, University of Ulm, Ulm, Germany., Baselga J; Memorial Sloan Kettering Cancer Center, New York, New York., Moreno-Aspitia A; Mayo Clinic, Jacksonville, Florida., Piccart-Gebhart M; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium., Gelber RD; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Harvard TH Chan School of Public Health, Boston, Massachusetts.; Frontier Science and Technology Research Foundation, Boston, Massachusetts., de Azambuja E; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium., Ignatiadis M; Department of Medicine, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium.

Publikováno v: Cancer [Cancer] 2019 Jan 15; Vol. 125 (2), pp. 307-316. Date of Electronic Publication: 2018 Oct 18.